Xencor, Inc. (XNCR)

Price$11.77

Value ScoreC

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-39.97%

Price vs S&P 500 (4W)-8.47%

VGM Score45.37

Market Capitalization$846.70M

All Metrics

Book Value / Share (Quarterly)$6.96

P/TBV (Annual)1.74x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-8.63%

Cash Flow / Share (Quarterly)$-2.55

Price vs S&P 500 (YTD)-31.28%

Net Profit Margin (TTM)-177.10%

EPS (TTM)$-2.30

10-Day Avg Trading Volume0.63M

EPS Excl Extra (TTM)$-2.30

Revenue Growth (5Y)0.46%

EPS (Annual)$-1.24

ROI (Annual)-12.17%

Net Profit Margin (5Y Avg)-73.27%

Cash / Share (Quarterly)$6.01

Revenue Growth QoQ (YoY)-86.20%

ROA (Last FY)-10.50%

Revenue Growth TTM (YoY)-25.35%

EBITD / Share (TTM)$-2.76

ROE (5Y Avg)-13.05%

Operating Margin (TTM)-222.36%

Cash Flow / Share (Annual)$-1.92

P/B Ratio1.64x

P/B Ratio (Quarterly)1.72x

Net Income / Employee (Annual)$-353,600

EV / Revenue (TTM)9.67x

Net Interest Coverage (TTM)-5.50x

ROA (TTM)-20.52%

EV / EBITDA (TTM)15.48x

EPS Incl Extra (Annual)$-1.24

Current Ratio (Annual)6.25x

Quick Ratio (Quarterly)6.22x

3-Month Avg Trading Volume0.77M

52-Week Price Return29.06%

Revenue / Employee (TTM)$374,500

Tangible BV / Share (Quarterly)$6.86

P/S Ratio (Annual)6.74x

Asset Turnover (Annual)0.14x

52-Week High$18.69

Operating Margin (5Y Avg)-88.36%

EPS Excl Extra (Annual)$-1.24

CapEx CAGR (5Y)-25.55%

Tangible BV CAGR (5Y)2.42%

26-Week Price Return-32.04%

Quick Ratio (Annual)6.02x

13-Week Price Return5.47%

Total Debt / Equity (Annual)0.19x

Current Ratio (Quarterly)6.57x

Enterprise Value$941.06M

Revenue / Share Growth (5Y)-4.64%

Asset Turnover (TTM)0.12x

Book Value / Share Growth (5Y)-2.20%

Revenue / Employee (Annual)$483,000

Pretax Margin (Annual)-71.38%

Cash / Share (Annual)$7.62

3-Month Return Std Dev60.18%

Net Income / Employee (TTM)$-663,200

ROE (Last FY)-14.46%

Net Interest Coverage (Annual)-1.51x

EPS Basic Excl Extra (Annual)$-1.24

P/FCF (TTM)4.72x

Receivables Turnover (TTM)3.91x

Total Debt / Equity (Quarterly)0.21x

EPS Incl Extra (TTM)$-2.30

Receivables Turnover (Annual)2.79x

ROI (TTM)-23.75%

P/S Ratio (TTM)8.70x

Pretax Margin (5Y Avg)-71.63%

Revenue / Share (Annual)$1.69

Tangible BV / Share (Annual)$8.73

Price vs S&P 500 (52W)4.69%

Year-to-Date Return-23.12%

5-Day Price Return-0.25%

EPS Normalized (Annual)$-1.24

ROA (5Y Avg)-9.08%

Net Profit Margin (Annual)-73.20%

Month-to-Date Return-0.93%

Cash Flow / Share (TTM)$-1.81

EBITD / Share (Annual)$-2.37

Operating Margin (Annual)-148.65%

LT Debt / Equity (Annual)0.12x

ROI (5Y Avg)-10.36%

LT Debt / Equity (Quarterly)0.16x

EPS Basic Excl Extra (TTM)$-2.30

P/TBV (Quarterly)1.74x

P/B Ratio (Annual)1.72x

Pretax Margin (TTM)-174.61%

Book Value / Share (Annual)$8.84

Price vs S&P 500 (13W)-2.79%

Beta0.94x

P/FCF (Annual)15.88x

Revenue / Share (TTM)$1.29

ROE (TTM)-28.77%

52-Week Low$6.92

vGradeC

gGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-1.71est. -0.79

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.20

4.15

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
XNCRXencor, Inc.	C	D	C	$11.77
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Xencor Inc is a clinical-stage biopharmaceutical company developing engineered antibody therapeutics for cancer and autoimmune diseases. The company leverages its proprietary XmAb technology platform to advance a pipeline of antibody candidates through clinical development. Xencor generates revenue through collaboration and licensing agreements with larger pharmaceutical partners, reducing development risk while advancing its research programs.